Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 11, 2012, Pages 2367-2374

  Lee, S ^a   Kim, D W ^a   Cho, B S ^a   Yoon, J H ^a   Shin, S H ^a   Yahng, S A ^a   Lee, S E ^a   Eom, K S ^a   Kim, Y J ^a   Chung, N G ^a   Kim, H J ^a   Min, C K ^a   Lee, J W ^a   Min, W S ^a   Park, C W ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Allogeneic transplantation; Imatinib; Minimal residual disease kinetics; Philadelphia chromosome positive acute lymphoblastic leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; HYDROCORTISONE; IDARUBICIN; IMATINIB; MELPHALAN; METHOTREXATE; MITOXANTRONE; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84869080402     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.164     Document Type: Article

References (31)

1. Thomas DA, FaDerl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396-4407. (Pubitemid 38745962)
2. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466. (Pubitemid 46630465)
3. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood 2006; 108: 1469-1477. (Pubitemid 44316110)
4. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413. (Pubitemid 46239571)
5. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28: 3644-3652.
6. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87-95.
7. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008; 93: 287-290. (Pubitemid 351397719)
8. Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer 2011; 117: 4009-4017.
9. Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 1997; 11: 294-298. (Pubitemid 27085176)
10. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357-2366.
11. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphiapositive acute lymphoblastic leukemia. Leukemia 2005; 19: 628-635. (Pubitemid 40521168)
12. Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003; 102: 3068-3070. (Pubitemid 37248885)
13. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449-3457. (Pubitemid 40628185)
14. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009; 115: 561-570.
15. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37. (Pubitemid 43990609)
16. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCRABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925-1930. (Pubitemid 44614879)
17. Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: Antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1083-1094. (Pubitemid 47215565)
18. Lee S, Chung NG, Cho BS, Eom KS, Kim YJ, Kim HJ et al. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia 2010; 24: 2110-2119.
19. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: Results of a prospective phase 2 study. Leukemia 2009; 23: 1763-1770.
20. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145-153. (Pubitemid 36056923)
21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
22. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233. (Pubitemid 40045609)
23. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
24. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
25. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 456-509.
26. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia unDergoing imatinib-combined chemotherapy. Br J Haematol 2008; 143: 503-510.
27. Gabert J, Beillard E, Van Der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357. (Pubitemid 38072573)
28. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338.
29. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963.
30. Pfeifer H, Wassmann B, Pavlova A, WunDerle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Blood 2007; 110: 727-734. (Pubitemid 47108165)
31. Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I et al. Philadelphiapositive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011; 96: 552-557.